cancer weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of cancer weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Data from J.H. Taylor et al provide new insights into cancer
December 18th, 2007
"Intravesical bacillus Calmette-Guerin (BCG) is a treatment option for superficial (<= T1) transitional cell carcinoma. Transitional cell carcinoma involving the prostatic urethra presents a treatment dilemma," scientists writing in the journal Clinical Genitourinary Cancer report. "Whereas prostatic urethral involvement might require radical cystectomy, select patients can be offered BCG and careful surveillance to preserve the bladder. We report long-term experience with BCG in this subset of patients with > 5-year follow-up. Twenty-eight patients with high-risk superficial bladder cancer and prostatic urethral involvement were treated with once-weekly...
Source: cancer weekly (2007-12-18)
|
